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Suppression of testicular function and sexual behavior by
vaccination against GnRH (EquityTM) in the adult stallion
Abstract
The aim of this study was to evaluate the effects of an anti-GnRH vaccine on testosterone concentration,
antibody titer, scrotal width, semen quality and sexual behavior in the stallion. Adverse reactions to the
vaccine were also determined. Eight clinically healthy sexually experienced stallions aged between 6
and 15 years from the National Stud in Avenches (Switzerland) were used. Five stallions were
immunized 3 times at an interval of 4 and 8 weeks, respectively, with 200 microg of a GnRH-protein
conjugate (EquityTM, CSL Limited, Australia) intramuscularly in the neck and 3 control animals
received an equivalent volume of saline solution. Plasma testosterone concentrations and GnRH
antibody titers as well as semen quality and libido were determined weekly during 1 year (52 weeks). In
addition, scrotal width was measured in all stallions before and 4, 8 as well as 12 months after first
vaccination. Our results demonstrate that in 4 stallions plasma testosterone started to decrease after the
second vaccination and remained suppressed for at least 6 months whereas one stallion showed no
effect. Until the end of the experiment 2 stallions reached prevaccination testosterone values. Antibody
titers varied individually in all 5 stallions and reached peak concentrations within 2 weeks after the third
vaccination. Scrotal width was significantly (P<0.05) lower in vaccinated than in control stallions 8
months after first vaccination. Semen quality started to decreased after the second vaccination and
improved towards the end of the experiment. In 4 stallions libido was clearly reduced after the second
immunization but normalized in 2 animals before the end of the study while 2 stallions continued to
show poor libido. From our results we conclude that three immunizations with Equity are well tolerated
in the stallion and may effectively suppress testosterone secretion and reduce semen quality as well as
sexual behavior. The inhibiting activity of Equity on these parameters is individually different and may
last for a minimum of 6 months.
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Abstract 
The aim of this study was to evaluate the effects of an anti-GnRH vaccine on testosterone 
concentration, antibody titer, scrotal width, semen quality and sexual behavior in the stallion. 
Adverse reactions to the vaccine were also determined. Eight clinically healthy sexually 
experienced stallions aged between 6 and 15 years from the National Stud in Avenches 
(Switzerland) were used. Five stallions were immunized 3 times at an interval of 4 and 8 
weeks, respectively, with 200µg of a GnRH-protein conjugate (EquityTM, CSL Limited, 
Australia) intramuscularly in the neck and 3 control animals received an equivalent volume of 
saline solution. Plasma testosterone concentrations and GnRH antibody titers as well as 
semen quality and libido were determined weekly during one year (52 weeks). In addition, 
scrotal width was measured in all stallions before and 4, 8 as well as 12 months after first 
vaccination. Our results demonstrate that in 4 stallions plasma testosterone started to decrease 
after the second vaccination and remained suppressed for at least 6 months whereas one 
stallion showed no effect. Until the end of the experiment 2 stallions reached prevaccination 
testosterone values. Antibody titers varied individually in all 5 stallions and reached peak 
concentrations within 2 weeks after the third vaccination. Scrotal width was significantly (P < 
0.05) lower in vaccinated than in control stallions 8 months after first vaccination. Semen 
quality started to decreased after the second vaccination and improved towards the end of the 
experiment. In 4 stallions libido was clearly reduced after the second immunization but 
normalized in 2 animals before the end of the study while 2 stallions continued to show poor 
libido. From our results we conclude that three immunizations with EquityTM are well 
tolerated in the stallion and may effectively suppress testosterone secretion and reduce semen 
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quality as well as sexual behavior. The inhibiting activity of EquityTM on these parameters is 
individually different and may last for a minimum of 6 months. 
 
Keywords: Stallion; testosterone; sexual behavior; semen quality; GnRH; vaccine 
 
1. Introduction 
The suppression of male reproductive function has long been an important issue in equine 
veterinary practice. In stallions, the main interest is primarily directed towards preventing 
aggressive and unwanted sexual behavior to make them easier to handle and to guarantee their 
level of performance in training or competition. Control of reproductive activity may either be 
achieved by surgical, hormonal or immunological castration (Stout and Colenbrander, 2004; 
Stout 2005). Surgical castration which is widely used throughout the world irreversibly 
eliminates the source of testicular steroids and sperm resulting in loss of reproductive 
potential. Furthermore, castration carries surgical risks, especially in older animals and it has 
been shown (Line et al., 1985) that the behavioral problems will not be resolved in all cases. 
A non invasive alternative to castration is the application of progestagens to suppress 
hypothalamic and anterior pituitary secretion of GnRH and LH, respectively thus decreasing 
testicular testosterone release (Brady et al., 1997; Squires et al., 1997). Since progestagens 
such as altrenogest must be given daily in high doses to control sexual behavior in older 
stallions (Miller at al., 1997) and because little is known about possible side effects, 
progestagen treatment has not been well accepted in practice. In addition, progestagen 
administration cannot be used in horses which are intended for human consumption and in 
many equine sporting events this treatment is considered as doping-offence. 
Another possibility of reducing LH- and testosterone secretion in the stallion is the 
application of GnRH antagonists (Hinojosa et al., 2001; Fortier et al., 2002). The effect on 
libido appears to be age-dependent being absent in mature stallions despite a dramatic fall in 
testosterone concentrations (Fortier et al., 2002). Treatment with high doses of a GnRH 
agonist can effectively desensitize the pituitary to GnRH (down-regulation) in various 
species. In the stallion, however, agonist treatment had either no (Brinsko et al., 1998) or only 
a limited suppressive effect (Montavon et al., 1990; Boyle et al., 1991) and occasionally even 
enhanced gonadotropin secretion (Roser and Hughes, 1991; Sieme et al., 2004). While results 
using hormones, antagonists or agonists are not satisfactory, a practical alternative for 
inhibiting male reproductive function is by active immunization against various hormones of 
 3
the hypothalamic-pituitary-gonadal axis (D’Occhio, 1993; Thompson, 2000). Experiments 
using different GnRH vaccines were first performed in cattle (Robertson et al., 1979, 1982), 
sheep (Lincoln and Frazer, 1979; Jeffcoate et al., 1982) and swine (Falvo et al., 1986; Caraty 
and Bonneau, 1986). In horses, Schanbacher and Pratt (1985) were the first to describe the 
successful vaccination against GnRH in a cryptorchid stallion. Until now, several studies have 
been published (Dowsett et al., 1991, 1996; Malmgren et al., 2001; Dalin et al., 2002; 
Clement et al., 2005; Turkstra et al., 2005; Imboden et al., 2006; Elhay et al., 2007) not only 
investigating the anti-GnRH effect on reproductive activity in the horse but also for the 
treatment of equine arteritis virus (EVA) shedder stallions (Burger et al., 2004, 2006). In 
2001, a GnRH vaccine (EquityTM, Pfizer Animal Health, Australia) for specific use in horses 
was licensed in Australia and New Zealand for the control of estrus in the mare. As 
comprehensive studies in the stallion are lacking, the aim of the present investigation was to 
evaluate the safety and efficacy of EquityTM in the stallion with special emphasis on plasma 
testosterone and antibody concentrations as well as on semen quality and sexual behavior. 
2. Material and methods 
2.1. Experimental design 
Eight clinically healthy and sexually experienced warmblood stallions from the National Stud 
in Avenches (Switzerland) aged between 6 and 15 years were used for the experiment. The 
animals were kept in box stalls bedded with straw and were fed hay or haylage, oats, barley, 
corn and pellets supplemented with minerals. Water was available at libitum. All animals 
were regularly exercised and had daily access to a paddock. Before the onset of the 
experiment the stallions were trained to mount the phantom and extragonadal sperm reserves 
were minimized by five daily semen collections (Hurtgen, 1992). Five stallions (A-E) were 
randomly allocated to a treatment group and 3 animals served as controls (F, G, H). 
Beginning in May collections of blood and semen were performed weekly for a period of one 
year. Scrotal width was measured using a calliper at the beginning of the experiment (May) 
and 4 (September), 8 (January) as well as 12 months (May) later. Subsequent to semen 
collections in weeks 1, 5 and 13 the stallions A-E were immunized with 1 ml (200 g GnRH-
protein conjugate) of a commercially available anti-GnRH vaccine (EquityTM, Pfizer Animal 
Health, Australia). Control animals received an equivalent volume of saline solution. All 
injections were applied intramuscularly into the neck. Adverse effects were monitored for 3 
days after injection by twice daily clinical examination with particular regard to body 
temperature, signs of tissue reaction at the site of injection and stiffness of the neck. All 
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animal experimentation was performed following approval from the local Animal Ethics 
Committee (Etat de Vaud, service vétérinaire, protocol approval number 1498). 
2.2. Semen collection and examination 
Once the stallion had mounted the phantom, semen was collected with an artificial vagina 
(model “Avenches”). Volume of the ejaculate was measured after removal of the gel fraction. 
Sperm concentration, total sperm number and total motility were assessed in freshly diluted 
(INRA 96, IMV, Aîgle, France) semen with a sperm analyzer (HTM-IVOS, Version 12, 
Beverly, MA, USA) using 20 micron standard count analysis chambers (Art. no. SC 20-01-C, 
Leja, Nieuw-Vennep, The Netherlands) and standardized threshold values for stallion semen. 
For morphological examination, three drops of fresh semen were fixed in 2 ml buffered 
formol saline solution (Na2HPO4 4.93 g, KH2PO4 2.54 g, 38% formaldehyde 125 ml, NaCl 
5.41 g, distilled water qs 1000 ml) and smears prepared. At least 200 spermatozoa were 
subsequently evaluated by phase contrast microscopy (Olympus BX50, UplanF1 100x/1.30) 
and abnormal spermatozoa classified in major (acrosome defects, nuclear vacuoles, abnormal 
heads, loose abnormal heads, abnormal midpieces, proximal droplets) and minor (loose 
normal heads, abnormal tails, distal droplets) defects (Blom, 1973; Jasko et al., 1990). 
2.3. Sexual behavior 
The stallions were exposed to the phantom in presence of an ovariectomized mare during 
maximal 10 min for each attempt to collect semen. Sexual behavior was measured as time to 
first erection and ejaculation. 
2.4. Testosterone analysis and GnRH antibody titers 
Blood samples (EDTA) were collected in the morning between 8 and 9 a.m. at each 
examination day by jugular venipuncture, immediately centrifuged (4000 x g, 10 min) and the 
plasma frozen (-20°C) until analysis. Testosterone was determined by 
electrochemiluminescence immunoassay (Elecsys 2010, Roche Diagnostics, Basel, 
Switzerland) as described earlier (Wang et al., 2004). The detection limit of the assay was 
0.02 ng/ml. All samples were analyzed using a biotinylated monoclonal antibody against 
testosterone. Cross-reactivity with estrogens and progesterone was < 0.01%, with 
androstendione 0.91% and with 5--dihydrotestosterone 1.89%. For validation of between 
assay precision a pooled sample was analyzed 6 times a day for a total of 10 days (n = 60) and 
for within assay precision pooled samples were measured 20 times a day (n = 20). Inter- and 
intraassay coefficients of variation were 2.2% and 1.4%, respectively. 
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Antibody titers against GnRH were determined using a radioligand binding assay as 
described previously (Finnerty, 1994). Results are presented as percentage of total 125I-
labelled GnRH bound at a plasma dilution of 1:40. 
2.5. Data analysis 
Data were analyzed using StatView 5.0 software program (SAS Institute, Wangen, 
Switzerland). A multivariate analysis of variance (ANOVA) was carried out to assess the 
effects of group allocation, time and vaccination (interaction between group allocation and 
time) on plasma testosterone concentrations and scrotal width. Between group differences 
were compared with unpaired t-test. Values were considered to be statistically significant at P 
< 0.05. Because of high individual variation antibody titers, plasma testosterone as well as 
total sperm number, motility and major sperm defects are shown for single animals. 
Testicular function was considered to be suppressed when testosterone values were lower than 
0.1 ng/ml for at least 2 consecutive weeks. After a period of testicular suppression stallions 
were judged as having resumed reproductive activity when they fulfilled the following 
criteria, a) plasma testosterone concentrations > 0.1ng/ml for at least 2 consecutive weeks, b) 
ejaculation of more than 500 million motile sperm within 10 min of exposure to the phantom 
and the ovariectomized mare. 
3. Results 
3.1. Adverse effects of the vaccine 
In the 5 stallions immunized with 1 ml EquityTM neither apathy nor pyrexia could be 
diagnosed following the first or booster vaccinations. One animal (B) reacted with a small not 
painful swelling after the first and third immunization and another stallion (D) had a sore 
swelling after the third injection. All adverse effects resolved within 2-3 days after 
appearance. There were no injection site reactions in the control stallions. 
3.2. GnRH antibody titer 
Antibody titers against GnRH in all vaccinated stallions are shown in Fig. 1. Titers started to 
rise immediately after the second vaccination and reached peak values between 14.6% and 
43.9% binding 2-4 weeks after the third vaccination. Thereafter the titers slowly decreased to 
values between 6.1% and 21.0% binding at week 51. The least antibody response with 
maximum values of only 15% binding occurred in stallion C. 
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Fig. 1. Anti-GnRH antibody titers (% binding at a 1:40 plasma dilution) in 5 stallions (A-E) 
after vaccination with EquityTM (). 
3.3. Testosterone 
Results from ANOVA demonstrate that weekly measured plasma testosterone concentrations 
were significantly influenced by group allocation (P < 0.0001), time of blood collection (P < 
0.0001) and by vaccination (interaction between group and time, P = 0.0003). The individual 
testosterone profiles in all vaccinated stallions are shown in Fig. 2a. Starting at 2 weeks after 
the second vaccination only low fluctuating concentrations (< 0.1-0.5 ng/ml plasma) were 
observed in 4 stallions. In one animal (C) the range of values was higher (< 0.1-1.2 ng/ml 
plasma) and testosterone not suppressed during the whole study. Regarding duration of 
suppression 2 stallions had low plasma testosterone (< 0.1 ng/ml) during 45 weeks (B, 7-52) 
and 46 weeks (D, 6-52) while in the other two animals suppression lasted for 24 weeks (A, 7-
31) and 36 weeks (E, 7-43), respectively. In control animals (Fig. 2b) testosterone secretion 
was episodic with fluctuations between 0.1 and 1.4 ng/ml plasma. 
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Fig. 2a. Individual blood testosterone concentrations of 5 stallions (A-E) after vaccination 
with EquityTM (). 
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Fig. 2b. Individual blood testosterone concentrations of the control stallions F, G and H. 
3.4. Sexual behavior 
In comparison to control stallions exhibiting normal sexual behavior including erection within 
1-3 minutes and ejaculation during the first mount in the presence of a mare, libido varied 
considerably in all vaccinated stallions. In all but one stallion (D) time to erection and 
ejaculation was negatively affected by GnRH vaccination and in 2 stallions (A and C) both 
parameters were temporarily (weeks 20-42) prolonged and occasionally no semen could be 
collected. During this period stallion A often needed several mounts until ejaculation and 
stallion C failed to ejaculate at all during weeks 26-42. However, in these two animals libido 
normalized towards the end of the experiment. In the remaining 2 stallions the interest for 
mares continuously decreased after the second vaccination and no ejaculation occured in 
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stallion B from week 29 until the end of the study (week 52) and in stallion E during weeks 
12-42. In control animals semen collection was possible during the whole study. 
3.5. Semen quality 
In all vaccinated stallions total sperm number fluctuated between 2 and 18 x 109 and 
decreased after the third vaccination (Fig. 3a). In control animals total sperm number varied 
between 2 and 17 x 109 throughout the whole experiment (Fig. 3b). With the exception of 
stallion C sperm motility began to decrease individually after the second and third vaccination 
and recovered to prevaccination values after week 40 (Fig. 4a). In control animals sperm 
motility fluctuated on an individually different but constant level during the whole study (Fig. 
4b). Changes in the percentage of major sperm defects in vaccinated stallions are shown in 
Fig. 5a. After immunization, an increase of major sperm defects was noticed in 3 stallions (A, 
B, D), while in stallion C a high percentage of major sperm defects (80-90%) was already 
present before the experiment started and these values were not affected by vaccination with 
EquityTM. All control animals showed a high percentage of major sperm defects with only 
minor fluctuations on a constant level. 
3.6. Scrotal width 
Scrotal width was significantly (P < 0.05) influenced by vaccination against GnRH 
(interaction between time and group allocation, P = 0.0073) but not by group allocation (P = 
0.1061) and time (P = 0.0515). Means (m  S.E.M.) of scrotal width in vaccinated animals 
decreased from 11.8  0.6 cm before to 8.8  1.0 cm and 8.0  0.8 cm and increased to 10.6  
0.5 cm, 4, 8 and 12 months after first vaccination, respectively (Fig. 6). In control stallions 
mean scrotal width ranged between 11.0  0.6 cm and 11.7  0.9 cm. A significant (P < 0.05) 
group difference was present 8 months after first vaccination. 
3.7. Resumption of reproductive activity 
Based on criteria defined in Material and methods only two vaccinated stallions A and E 
regained reproductive activity at weeks 34 and 43, respectively. In stallions B and D testicular 
function remained suppressed until the end of the study. 
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Fig. 3a. Total sperm number in weekly collected ejaculates of 5 stallions (A-E) after 
vaccination with EquityTM (). 
0
4
8
12
16
20
0
4
8
12
16
20
0
4
8
12
16
20
2
6
10
14
18
2
6
10
14
18
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51
Week
stallion A
stallion B
stallion C
stallion D
stallion E
 May     Jun      Jul      Aug     Sep     Oct       Nov     Dec      Jan     Feb      Mar     Apr 
To
ta
l s
pe
rm
 n
um
be
r (
bi
llio
ns
) 
 11
 
 
Fig. 3b. Total sperm number in weekly collected ejaculates of the control stallions F, G and 
H. 
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Fig. 4a. Total sperm motility in weekly collected ejaculates of 5 stallions (A-E) after 
vaccination with EquityTM (). 
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Fig. 4b. Total perm motility in weekly collected ejaculates of the control stallions F, G and H. 
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Fig. 5a. Major sperm defects (%) in weekly collected ejaculates of 5 stallions (A-E) after 
vaccination with EquityTM (). 
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Fig. 5b. Major sperm defects (%) in weekly collected ejaculates of the control stallions F, G 
and H. 
 
 
Fig 6. Scrotal width (m  S.E.M.) in 5 vaccinated () and 3 control () stallions before, 4, 8 
and 12 months after the first vaccination with EquityTM. *Significant difference between 
groups (P < 0.05, t- test). 
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4. Discussion 
Results of our study demonstrate that administration of the GnRH vaccine EquityTM to adult 
stallions reduces testosterone secretion, scrotal width as well as semen quality and sexual 
behavior. The immune response to vaccination, however, was characterized by considerable 
variation as depicted in the profiles of the individual animals. 
Unwanted side effects including minor swelling at the injection site lasting for only 2 to 3 
days were observed in 2 stallions. The high degree of safety when using EquityTM in horses 
agrees with a recently published study in mares (Elhay et al., 2007) showing that only 10 of 
24 vaccinated mares reacted with a transient slightly raised and flat swelling of the skin 
following first or second immunization. In contrast, the application of ImprovacTM (Imboden 
et al., 2006) or other GnRH vaccine formulations (Dowsett et al., 1991, 1996; Dalin et al., 
2002) in the horse may cause severe adverse effects as pyrexia, apathy and stiffness of the 
neck and should therefore not be used in horses. 
First successful vaccination of a cryptorchid stallion against GnRH was reported by 
Schanbacher and Pratt (1985), but several booster injections were required to suppress 
testosterone secretion. This vaccine contained Freunds adjuvant and inhibition of testosterone 
lasted 4 months. Because of severe reactions at the site of injection other vaccine formulations 
containing a water-soluble adjuvant were subsequently developed. Using such a vaccine in 2-
year-old colts (Dowsett et al. 1996) testicular function as well as sexual behavior and libido 
were individually suppressed for 12 to 26 weeks after two to three immunizations. In our 
study using the commercially available horse specific vaccine (EquityTM) given three times, 
testosterone concentrations were suppressed (< 0.1 ng/ml) for a minimum of 24 weeks in 4 of 
5 adult stallions. In 2 animals (B, D) testosterone remained low for 45 and 46 weeks, 
respectively. One stallion (C) showed a very poor rise in antibody titer without any visible 
effect on testosterone secretion. This clearly shows that the application of EquityTM  in adult 
stallions may elicit variable immune responses with different antibody titers and different 
duration of testosterone suppression. 
A negative influence of GnRH immunization on semen quality was observed in 4 of 5 
stallions and the drop of total sperm number and sperm motility as well as the increase in 
major sperm defects varied considerably between single animals. These results agree with 
others studies (Dowsett et al., 1996; Malmgren et al., 2001; Clement et al., 2005; Turkstra et 
al., 2005) showing that good responders (high antibody titers) reacted with a reduced semen 
quality. In our experiment the most dramatic decrease in sperm motility from 79% to 3% 
within 6 months after the first vaccination occurred in stallion B and this animal also had a 
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marked increase in major sperm defects. Lower sperm production, lower sperm motility 
and an increase in sperm abnormalities are in accordance with low testosterone concentrations 
caused by high circulating antibody titers. These results confirm the essential role of 
testosterone for spermatogenesis and epididymal function but leaves the question open why 
the changes in semen quality were highly variable between individual stallions despite 
constant low testosterone concentrations for more than 6 months. A possible explanation 
might be the different effect of GnRH immunization on pituitary LH and FSH secretion 
(Garza et al., 1986; Rabb et al., 1990). Because FSH is less affected by GnRH, circulating 
FSH together with low testosterone concentrations may be sufficient to maintain 
spermatogenesis. 
Regarding sexual behavior the application of EquityTM reduced libido in 4 of 5 stallions. 
Interestingly enough, in stallion C which had the lowest antibody titers and highest 
testosterone concentrations, libido and mounting behavior were markedly reduced during 
weeks 26-39. Quite the opposite situation was observed in stallion D which exhibited strong 
sexual and mounting behavior during the whole experiment in spite of high antibody titers 
and low testosterone values. From these findings it is obvious that sexual behavior is not only 
testosterone dependent but may rather be influenced by various others factors as age of the 
animal and previous sexual experience (Stout, 2005). Looking at other studies in which 
GnRH vaccination had either no (Clement et al. 2005) or only a limited effect (Malmgren et 
al., 2001; Turkstra et al., 2005) on libido, the use of EquityTM in our experiment was more 
successful to control stallion behavior. However, because of differences in vaccine 
formulations and dosage, number of boosters as well as age, breed and number of vaccinated 
stallions comparison of results between these studies is difficult. 
5. Conclusion 
This study demonstrates that 3 immunizations with EquityTM are well tolerated and can 
reliably suppress testicular function and sexual behavior in adult sexually experienced 
stallions. The inhibitory effect, however, is highly variable and may last from a minimum of 
24 weeks to more than 46 weeks. 
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